Regeneron Pharmaceuticals

This study follows 858 people with atopic dermatitis (eczema) who are starting treatment with Dupixent. Researchers track how well the drug works and any side effects over time in everyday medical practice. Participants include teens and adults, and the goal is to understand long…

This program provides continued access to dupilumab for adults with severe IgE-mediated food allergy who were previously treated with linvoseltamab and dupilumab in an earlier study. The goal is to keep offering the medication to eligible participants who completed the parent stu…

This program offers evinacumab to children and adults with severe inherited cholesterol or triglyceride conditions who have run out of treatment options. The goal is to lower dangerously high lipid levels and reduce the risk of heart attacks or pancreatitis. Participants receive …

This program gives patients with advanced melanoma that hasn't responded to standard treatments access to an experimental drug called vidutolimod. The goal is to provide a potential treatment option when no others are available. The study is no longer enrolling participants.

This study tests whether a combination of two experimental drugs (fianlimab and cemiplimab) works better than the current standard treatment (pembrolizumab) for people with advanced melanoma that cannot be removed by surgery. About 1,500 adults and teens with untreated advanced m…

This study was designed to test the safety of an experimental drug called garetosmab in healthy men and postmenopausal women with obesity. Researchers planned to measure side effects, drug levels in the blood, and effects on hormones and blood clotting. However, the study was wit…

This early-phase study tests the safety and effectiveness of cemiplimab, an immunotherapy drug, alone or combined with other agents in Japanese patients with advanced lung cancer. The goal is to see if these treatments can shrink tumors by helping the immune system attack cancer …

This study tests whether adding an experimental drug (fianlimab) to standard immunotherapy (cemiplimab) and chemotherapy works better than the standard combination alone for people with early-stage lung cancer that can be removed by surgery. About 195 participants will receive tr…

This program provides expanded access to cemiplimab, a cancer drug, for people with non-small cell lung cancer, basal cell carcinoma, or cutaneous squamous cell carcinoma who have no other treatment options. The goal is to make the drug available to those who cannot join a clinic…

This study tests whether adding an experimental drug (fianlimab) to a standard immunotherapy (cemiplimab) works better than the standard drug alone for people with advanced non-small cell lung cancer that has high levels of a protein called PD-L1. About 850 participants will rece…

This program offers compassionate use of dupilumab to people with severe type 2 inflammatory disorders who have no other treatment options. The goal is to provide access to this medication for those who cannot join a clinical trial. Participants receive dupilumab to help control …

This study tests whether adding trevogrumab (with or without garetosmab) to the weight-loss drug semaglutide (Wegovy) helps people with obesity lose more fat while preserving muscle. About 1005 participants will be enrolled across three parts, including healthy volunteers and peo…

This study tests a new experimental drug, odronextamab, combined with chemotherapy for people with follicular lymphoma who have not yet been treated. The goal is to see if this new combination works better than the current standard treatment (rituximab plus chemotherapy). About 7…

This study tests an experimental drug called ALN-ANG3 in healthy adults with high cholesterol or triglycerides. The main goal is to check if the drug is safe and tolerable, and to see how it moves through the body. About 59 participants will receive either the drug or a placebo. …

This trial gives people with CD55-deficient protein-losing enteropathy access to an experimental drug called pozelimab. The condition causes the gut to leak proteins, leading to serious health problems. The goal is to control the disease and improve symptoms.

This early-stage study tests two experimental drugs, odronextamab and cemiplimab, in about 105 people with aggressive B-cell lymphoma that has come back or not responded to prior treatments. The main goal is to see if the combination is safe and tolerable, and to find the best do…

This study tests a combination of two experimental drugs, pozelimab and cemdisiran, in people with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder. The goal is to see if this new combo works better and is safer than current standard treatments (ravulizumab and ec…

This program offers garetosmab to adults with fibrodysplasia ossificans progressiva (FOP) who finished a previous study. The goal is to provide the drug before it is officially approved. Participants must meet specific health criteria to join.

This study tests whether giving the drug cemiplimab (alone or with another drug called fianlimab) before surgery can shrink tumors in people with lung, liver, or head/neck cancers. About 65 participants will receive the treatment and then have surgery. Researchers will check how …

This program provides access to an experimental drug called pozelimab for people with CHAPLE disease, a rare and life-threatening immune disorder that causes protein loss from the gut. The goal is to offer treatment and track long-term safety. Participants must have a confirmed g…

This study looks at 120 adults with asthma that is not well controlled by their current medium-dose inhaler. Researchers want to see if adding the injectable drug dupilumab to the usual inhaler works better than simply increasing the inhaler dose. The goal is to reduce severe ast…

This study tests a new drug called mibavademab in 9 adults with generalized lipodystrophy (GLD), a rare condition where the body cannot store fat properly. Participants switch from their current treatment (metreleptin) to mibavademab to see if it is safe and tolerable. The goal i…

This program provides access to a combination of two drugs, pozelimab and cemdisiran, for people with paroxysmal nocturnal hemoglobinuria (PNH), a rare immune disease that destroys red blood cells. It is for patients who have already completed a related study and aims to monitor …

This study tests whether adding an experimental drug (fianlimab) to standard immunotherapy (cemiplimab) and chemotherapy can better control advanced non-small cell lung cancer. About 950 adults who have not had prior treatment for advanced disease will receive either the triple c…

This study tests a higher dose of the drug aflibercept (8 mg) given as an eye injection every 4 weeks. It includes about 1,100 adults with wet age-related macular degeneration (nAMD) or diabetic macular edema (DME) who have already received anti-VEGF treatment. The main goal is t…

This study tests two experimental drugs, pozelimab and cemdisiran, alone or together, in 288 adults with generalized myasthenia gravis (gMG), a disease that causes muscle weakness and fatigue. The goal is to see if these drugs improve daily activities and muscle strength. Partici…

This study tests an experimental drug called garetosmab in 63 adults with fibrodysplasia ossificans progressiva (FOP), a rare genetic condition where soft tissues turn into bone. The goal is to see if the drug safely reduces new abnormal bone growth and flare-ups. Participants re…

This study tests an investigational drug called linvoseltamab in 40 people with high-risk smoldering multiple myeloma, a condition that often leads to active cancer. The goal is to see if the drug can safely eliminate abnormal plasma cells and prevent progression to multiple myel…

This study tests an experimental drug called REGN7041 in people with active eye inflammation (uveitis) that is not caused by an infection. The main goal is to see if the drug is safe and tolerable, since this is the first time it's been tested in humans. Researchers will also mea…

This study was designed to see if the eczema drug dupilumab could help children aged 6 to 12 with severe eczema grow taller and have stronger bones. The drug is already approved for eczema in this age group. However, the study was withdrawn before any participants were enrolled, …

This study tests whether an immunotherapy drug called cemiplimab can help prevent high-risk skin cancer (cutaneous squamous cell carcinoma) from returning after surgery and radiation. About 415 participants will receive either cemiplimab or a placebo. The main goal is to see if t…

This program gives patients with relapsed or refractory multiple myeloma access to REGN5458 before it is fully approved. It is for those who have tried other treatments and have no good options left. The goal is to control the disease and improve outcomes.

This study tests an experimental drug called dupilumab in 22 adults and teens (12+) with eosinophilic gastritis, a rare allergic condition that causes stomach inflammation. The goal is to see if the drug can reduce symptoms and lower the number of inflammatory cells in the stomac…

This study tests whether combining two immunotherapy drugs (fianlimab and cemiplimab) works better than one drug alone for people with high-risk, removable melanoma. About 151 participants will receive treatment before surgery, then continue after. The goal is to see if the combi…

This study tests an experimental drug called odronextamab in adults with B-cell non-Hodgkin lymphoma whose cancer has returned or not responded to prior treatments. The goal is to see how well the drug shrinks tumors and to check its safety. About 515 participants will receive th…

This study tests whether adding an experimental drug, BNT116, to the standard immunotherapy cemiplimab works better than cemiplimab alone for people with advanced non-small cell lung cancer. About 51 participants with a specific tumor marker (PD-L1 ≥50%) will receive either the c…

This study tests an experimental drug called REGN7544 in 82 adults with Postural Orthostatic Tachycardia Syndrome (POTS). The goal is to see if a single dose can safely reduce the abnormal heart rate increase that happens when standing up. Researchers will also monitor side effec…

This study follows 48 people with advanced melanoma who previously received the experimental drug combination fianlimab plus cemiplimab in an earlier trial. No new treatment is given; researchers track cancer status, overall health, and any late side effects over time. The goal i…

This early-stage study tests whether a new drug, ALN-F1202, is safe and tolerable in healthy adults. Researchers will monitor side effects, how the drug moves through the body, and the best dose. Participants are healthy volunteers, not patients seeking treatment.

This study follows about 100 infants who were previously treated for retinopathy of prematurity (ROP), an eye condition in premature babies. Researchers want to see how their eyesight and overall development are doing over the long term. No new treatments are given—this is an obs…

This study looks at men with Hemophilia B who are already on regular factor IX therapy to prevent bleeding. Researchers will track bleeding events, treatment use, and quality of life for at least 6 months. No experimental treatment is given—the goal is to gather information for f…

This study looks back at medical records of about 1,000 people with advanced non-small cell lung cancer who received a combination of the drug cemiplimab and chemotherapy. The goal is to see how safe and effective this treatment is in different groups based on age, sex, race, and…

This study tracks 718 asthma patients who are starting the medication DUPIXENT in real-world settings, not in a controlled lab. Researchers want to learn about the patients' backgrounds, how they use the drug, and how well it works over time. The goal is to gather long-term safet…